Drug Database
ME

medroxyprogesterone + Premarin (Premella / Premelle Ciclico / Premique Cycle)

✓ Approved

Pfizer, Inc. · ESR1 · 小分子

什么是 medroxyprogesterone + Premarin?

medroxyprogesterone + Premarin 是一种小分子,由Pfizer, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Premella, Premelle Ciclico, Premique Cycle
公司Pfizer, Inc.
药物类别小分子
分子靶点ESR1, PGR
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

medroxyprogesterone + Premarin 作用于 2 个分子靶点:

ESR1estrogen receptor 1 (ER, ESR)
PGRprogesterone receptor (NR3C3, PR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

medroxyprogesterone + Premarin 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresHormone replacement therapy✓ Approved
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

相关研究文献

PubMedContraception2026-11-12

The association between antiretroviral therapy regimen and contraceptive failure among Malawian women living with HIV using injectable, progestin-based hormonal contraception.

Diepstra Karen K, Westreich Daniel D, Cottrell Mackenzie M, Pettifor Audrey A et al.

Drug-drug interactions between antiretroviral therapy (ART) and hormonal contraceptives are critical to understand for women with HIV (WWH) who do not desire pregnancy. One hormonal contraceptive commonly used among WWH in sub-Saharan Africa is depot medroxyprogesterone acetate (DMPA). We aimed to estimate the effect of efavirenz- versus dolutegravir-based ART on pregnancy incidence among Malawian WWH using DMPA contraception and ART as prescribed. Using Family Planning and Antiretroviral Therapy (FP-ART) cohort data, we identified participants who initiated DMPA at enrollment and followed participants until DMPA or ART discontinuation, occurrence of first pregnancy, self-reported pregnancy intention of "now" or "in the next year", study dropout, or administrative censoring. We examined the time-varying exposure of ART regimen type (tenofovir disoproxil fumarate and lamivudine, with either efavirenz or dolutegravir). The outcome was clinically-detected pregnancy. We used inverse probability weights to fit marginal structural Poisson regression models to estimate incidence rate ratios (IRRs). 689 participants initiated DMPA at enrollment; 41 pregnancies were captured during 827 person-years of follow-up (crude incidence rate: 5.0/100 person-years, 95% confidence interval [CI]: 3.7, 6.7; crude efavirenz rate: 6.1 conceptions per 100 person-years, 95% CI: 4.3, 8.7; crude dolutegravir rate: 3.3 conceptions per 100 person-years, 95% CI: 1.8, 5.9). Restricted to person-time where DMPA was taken as prescribed, the crude incidence rate was 4.4/100 person-years (95% CI: 3.1, 6.2). The weighted IRR for consistently using efavirenz-based ART versus dolutegravir-based ART among those taking DMPA as prescribed was 1.90 (95% CI: 0.67, 5.40). Among WWH who were taking DMPA as prescribed, we did not find evidence of an elevated pregnancy rate with continuous efavirenz- versus dolutegravir-based ART use, however the 95% confidence intervals were wide. Further understanding causes of contraceptive failure among WWH who use DMPA and ART is essential. This work contributes to the growing evidence of possible drug-drug interactions between depot medroxyprogesterone acetate (DMPA) and antiretroviral medications, such as efavirenz. This analysis underscores the safety of dolutegravir-based antiretroviral therapy.

PMID 43020170
阅读全文 →
PubMedMaturitas2026-11-10

Risk of colorectal cancer and systemic menopausal hormone therapies: a Finnish cohort study.

Siitonen Heli H, Joensuu Johanna M JM, Savolainen-Peltonen Hanna H, Ylikorkala Olavi O et al.

We assessed the impact of menopausal hormone therapies (MHTs) on the risk of colorectal cancer (CRC) in Finnish women. In addition, we analysed various MHT characteristics in relation to risk and anatomic site of CRC. Users of MHT and age-matched non-users (both groups n = 364,304) in 1994-2019 were identified from the Finnish Medicine Reimbursement Register and the National Population Register. Cohorts were followed for the occurrence of primary CRC from the Finnish Cancer Registry. CRC risks were calculated as hazard ratios (HRs) and 95% confidence intervals (CIs) with a Cox proportional hazards model. Over a mean 18-year follow-up (13 million person-years), 4602 MHT users (1.3%) and 5103 non-users (1.4%) were diagnosed with CRC (p < 0.001). Ever use of MHT for 5 years or more was associated with a decreased CRC risk (HR 0.88, 95% CI 0.85-0.92). Estrogen-only therapy (ET) (0.81, 0.76-0.87) showed a larger risk reduction than combined estrogen-progestogen therapy (EPT) (0.92, 0.88-0.96). Tibolone was accompanied by the greatest risk decrease (0.54, 0.41-0.73), but the number of users was modest. Dydrogesterone EPT tended to confer 31-36% lower CRC risk than EPTs containing norethisterone or medroxyprogesterone acetate. Risk reductions were of similar magnitude for right- and left-sided colon cancer, but rectal cancer risk was decreased only with 10 or more years of MHT use. The risk falls persisted for over 5 years after the cessation of MHT use. Use of ET or EPT for 5 years or more is associated with reduced CRC risk, likely mediated by estrogen, while some progestogens - but not dydrogesterone - may attenuate this effect.

PMID 43008428
阅读全文 →
PubMedReproductive biology and endocrinology : RB&E2026-11-04

Effects of progestin-primed ovarian stimulation protocol plus clomiphene citrate in patients with low basal LH levels: a randomized controlled trial.

Hu Zhijie Z, Fan Yong Y, Zhou Xiaoqian X, Guo Haiyan H et al.

Infertile patients with low basal luteinizing hormone (LH) levels have low oocyte retrieval rate, but whether progestin-primed ovarian stimulation (PPOS) protocol with clomiphene citrate (CC) could enhance oocyte retrieval rate in these patients remains unclear. This prospective randomized controlled trial was performed between January 2018 and February 2021, included 230 infertile patients with low basal LH levels (LH < 2.27 mIU/mL). In study group, 115 patients received human menopausal gonadotropin (hMG) 150 or 225 IU/d + CC 50 mg/d + medroxyprogesterone acetate (MPA) 10 mg/d from the third day of menstruation. In control group, 115 patients received hMG 150 or 225 IU/d + MPA 10 mg/d from the third day of menstruation. Viable embryos were cryopreserved for later transfer. The primary outcome measure was the oocyte retrieval rate. CC contributed to LH secretion. The hMG+MPA+CC group showed a decreased oocyte retrieval rate (0.71 ± 0.22 vs. 0.76 ± 0.18, mean difference (MD) -0.06 (-0.11 to -0.01); P = 0.043) and a decreased number of cryopreserved embryos (2.89 ± 2.43 vs. 3.90 ± 2.39, MD -0.89 (-1.50 to -0.28); FDR-P = 0.035). Two groups had similar number of retrieved oocytes (8.83 ± 5.41 vs. 10.69 ± 5.85, MD -0.99 (-2.27 to 0.29); FDR-P = 0.213) and oocyte utilization rate (0.40 ± 0.25 vs. 0.46 ± 0.24, MD -0.07 (-0.14 to -0.01); FDR-P = 0.084). Two groups had comparable cumulative clinical pregnancy rates (61.05% vs. 77.67%, hazard ratio (HR) 0.74 (0.53 to 1.06); P = 0.101; FDR-P = 0.214) and cumulative live birth rates (53.68% vs. 66.02%, HR 0.77 (0.53 to 1.13); P = 0.183; FDR-P = 0.214). CC contributed to LH secretion, but PPOS protocol with CC resulted in a lower oocyte retrieval rate in patients with low basal LH levels. PPOS protocol with CC should be used cautiously in these patients. ChiCTR number: ChiCTR1800014440. URL: https://www.chictr.org.cn/showproj.html?proj=24573 . Date of registration: 2018/01/13. Date of enrollment of the first subject: 2018/1/17.

PMID 42978013
阅读全文 →
PubMedFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026-10-30

Progestogens Modulate the Metabolic but Not the Musculoskeletal Response to Estradiol in a Mouse Model of Adolescent Gender Transition.

Calvo Blanco Sandra S, Nobus Oriana O, Zhang Boya B, Tuypens Karo K et al.

Gender-affirming hormone therapy in transgender girls typically consists of gonadotropin-releasing hormone analog (GnRHa)-mediated puberty suppression followed by estradiol (E2) treatment. While the skeletal effects of this approach have been investigated, its impact on skeletal muscle and metabolism remains unclear. Moreover, the addition of a progestogen such as natural progesterone (P4) or synthetic medroxyprogesterone acetate (MPA) to the standard E2 regimen has gained popularity due to presumed enhanced feminization, despite limited evidence regarding its effects on musculoskeletal and metabolic tissues. Here, we used a mouse model of adolescent male-to-female transition to address these questions. Peripubertal male mice were treated with a GnRHa to suppress endogenous sex hormone production, followed by E2 alone or in combination with P4 or MPA. Puberty suppression reduced the acquisition of bone mass and strength, impaired endurance capacity, decreased lean mass, altered muscle fiber type composition, and increased adiposity. E2 treatment increased bone outcomes to female control levels, and partially normalized endurance capacity, body composition, and metabolic parameters. Addition of a progestogen did not further affect bone or muscle outcomes beyond E2 alone. In contrast, progestogen co-administration worsened metabolic parameters, resulting in increased adiposity, impaired glucose tolerance, elevated fasting glucose and insulin, and hepatic lipid accumulation. These effects were more pronounced with MPA than with P4. In conclusion, E2 drives musculoskeletal recovery following puberty suppression, whereas progestogens do not provide additional benefits in these tissues. However, they adversely affect metabolic outcomes, highlighting the need for careful evaluation when these compounds are included in gender-affirming therapy.

PMID 42961372
阅读全文 →
PubMedInternational journal of biological macromolecules2026-10-28

SMAD family member 9 restrains MYC-associated zinc finger protein-driven Wnt family member 7A transcription in endometrial carcinoma.

Zhen Junling J, Nie Lekai L, Wang Yahao Y, Cai Meijuan M

Endometrial carcinoma (EC) is a common gynecological malignancy with increasing incidence and limited treatment options for advanced disease. The molecular mechanisms underlying its progression remain incompletely understood. Here, we identify SMAD family member 9 (SMAD9, also known as SMAD8) as a negative regulator of EC progression. Integrated analyses of clinical datasets and patient samples showed that SMAD9 is consistently downregulated in EC, and higher SMAD9 expression is associated with a more favorable prognosis. Functional assays showed that SMAD9 suppresses EC cell proliferation and cell-cycle progression, whereas its silencing enhances these phenotypes. Mechanistically, DNMT3B-mediated promoter hypermethylation contributes to reduced SMAD9 expression in EC. RNA sequencing and subsequent validation identified WNT7A as a downstream target of SMAD9. SMAD9 represses WNT7A expression and attenuates Wnt/β-catenin signaling, whereas MAZ binds to the WNT7A promoter and promotes its transcription. SMAD9 also associates with SMAD4, MAZ, and TOB1, accompanied by reduced MAZ occupancy at the WNT7A promoter. In addition, medroxyprogesterone acetate (MPA) increased SMAD9 expression and inhibited EC growth both in vitro and in xenograft models. MPA did not significantly alter SMAD9 promoter methylation using MethylTarget analysis, whereas PGR knockdown markedly attenuated the MPA-induced SMAD9 upregulation, suggesting that PGR signaling is required for MPA-induced SMAD9 expression. Together, these findings identify a DNMT3B-SMAD9-MAZ-WNT7A regulatory network linking epigenetic regulation of SMAD9 with transcriptional control of Wnt signaling in EC.

PMID 42950916
阅读全文 →
PubMedAnnales d'endocrinologie2026-10-23

Cardiovascular and thromboembolic risks of sex hormone therapy: from contraception to transgender care.

Bonnet Fabrice F, Vaduva Patricia P, Dosda Arnaud A

The risk of venous thromboembolism is increased with combined oral contraceptives, rises with the dose of ethinylestradiol, and is higher with desogestrel, gestodene, drospirenone or cyproterone acetate than with levonorgestrel; the determinant is not the generation of the pill but the residual androgen-receptor activity of the progestin, which modulates the hepatic effect of the estrogen. Age over 35 years, obesity, smoking and a family history of thrombosis amplify it. Pills based on a native estrogen have a more limited hepatic impact and rank below most ethinylestradiol combinations in contemporary cohorts, but their clinical safety is not demonstrated and no comparative outcome data exist for estetrol/drospirenone. Androgenicity is not a general marker of venous safety: injectable depot medroxyprogesterone acetate, given alone at supraphysiological doses, carries an increased risk. Myocardial infarction and stroke are also more frequent, but against a very low background - about 21 additional strokes and 10 additional infarctions per 100,000 person-years, four times fewer than the venous excess - and, unlike venous events, independent of progestin type. Menopause hormone therapy increases venous thromboembolic risk, especially in the first year; the route of administration is the main determinant, transdermal estradiol with micronized progesterone appearing safest. In cisgender men, testosterone deficiency carries increased cardiovascular risk, and randomized and real-world data support the safety of transdermal replacement, although more pulmonary embolism and atrial fibrillation have been observed. In trans women, observational data show an increased risk of stroke and venous thromboembolism, particularly with oral estradiol and cyproterone acetate, whereas recent large-scale data show no excess of major cardiovascular events with testosterone in trans men. The practical consequences are specific: no combined pill is acceptable after a venous thromboembolic event, with a thrombogenic mutation or with migraine with aura, native-estrogen pills included; transdermal estradiol should be preferred for menopause and feminising hormone therapy; and haematocrit should guide the dose and route of testosterone.

PMID 42918571
阅读全文 →

注册免费账户还可查看另外 7275 篇文献

免费注册查看全部文献 →

了解更多medroxyprogesterone + Premarin